Intravenous thrombolytics for ischemic stroke

Area of Science:

• Neurology
• Cardiology
• Pharmacology

Background:

• Intravenous (IV) thrombolytics have a long history in treating acute thrombosis, initially for coronary thrombosis.
• Their application has expanded to other conditions, notably ischemic stroke, adapting cardiology treatment paradigms.
• The primary goal is to recanalize occluded arteries and restore perfusion to salvageable brain tissue.

Purpose of the Study:

• To review the established and emerging use of IV thrombolytics in acute ischemic stroke.
• To discuss the challenges and ongoing research in optimizing thrombolytic therapy for stroke.
• To highlight the critical balance between achieving reperfusion and mitigating hemorrhage risk.

Main Methods:

• Review of historical adoption of IV-thrombolysis for ischemic stroke, referencing key studies like the National Institute of Neurological Disorders and Stroke study.
• Discussion of the development and testing of novel IV-thrombolytic agents.
• Evaluation of ongoing research into adjunctive treatments for acute ischemic stroke.

Main Results:

• Widespread adoption of IV-thrombolysis for ischemic stroke began in the late 1990s.
• Despite development, no new IV-thrombolytics have surpassed placebo efficacy in trials since initial adoption.
• Research continues to explore adjunctive treatments to improve outcomes.

Conclusions:

• IV-thrombolysis remains a cornerstone for acute ischemic stroke treatment, mirroring cardiac interventions.
• The efficacy of new thrombolytic agents has not yet surpassed established treatments.
• Future efforts focus on enhancing reperfusion strategies while carefully managing the risk of intracranial hemorrhage.